oxycodone extended-release

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:drug opioid
gptkbp:activeIngredient	gptkb:oxycodone
gptkbp:approvedBy	1995 (OxyContin, US)
gptkbp:brand	gptkb:OxyContin gptkb:Xtampza_ER
gptkbp:contraindication	paralytic ileus acute or severe bronchial asthma severe respiratory depression
gptkbp:controlledSubstanceSchedule	gptkb:Schedule_II_(US)
gptkbp:drugInteraction	gptkb:beer gptkb:CNS_depressants CYP3A4 inhibitors
gptkbp:excretion	kidneys
gptkbp:form	extended-release tablet extended-release capsule
gptkbp:halfLife	4.5-6.5 hours (extended-release)
https://www.w3.org/2000/01/rdf-schema#label	oxycodone extended-release
gptkbp:legalStatus	prescription only
gptkbp:manufacturer	Collegium Pharmaceutical (Xtampza ER) Purdue Pharma (OxyContin)
gptkbp:mechanismOfAction	mu-opioid receptor agonist
gptkbp:metabolism	liver
gptkbp:pregnancyCategory	C (US)
gptkbp:riskFactor	addiction respiratory depression
gptkbp:routeOfAdministration	oral
gptkbp:sideEffect	nausea constipation drowsiness
gptkbp:usedFor	pain management
gptkbp:bfsParent	gptkb:OxyContin
gptkbp:bfsLayer	7